The U.S. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases recommends that hospitalized patients with influenza indications undergo influenza testing when influenza is circulating in the community, and the Infectious Disease Society of America recommends rapid influenza molecular assays or reverse transcriptase polymerase chain reaction testing for greatest diagnostic certainty. The National Center for Immunization and Respiratory Diseases indications include typical influenza symptoms, atypical presentations, complications, and admission status. Three scenarios to consider: perform molecular testing if a patient has signs and symptoms suggestive of influenza, including an atypical clinical presentation, or findings suggestive of complications associated with influenza and is being admitted to the hospital; perform molecular testing if a patient has signs and symptoms suggestive of influenza and is not being admitted to the hospital but the result will influence clinical management; and if a patient is not symptomatic, then influenza testing is probably not indicated.